By Fineline Cube 
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., announced that the New Drug Application (NDA) for its sonrotoclax has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Mechanism of Action
Sonrotoclax is a BCL2 inhibitor designed to block the BCL2 protein, which helps tumor cells survive. Abnormal high expression of the BCL2 protein is widely present in various hematological malignancies, including CLL/SLL. This protein creates a favorable environment for tumor cells to survive and proliferate by blocking the apoptosis program. BCL2 inhibitors, such as sonrotoclax, can specifically bind to and inhibit the BCL2 protein, effectively restoring the apoptotic pathway of tumor cells and inducing cancer cell death.-Fineline Info & Tech